Importance of Dedicated Units for the Management of Patients With Inherited Arrhythmia Syndromes.
Giulio Conte, Arthur Wilde, Elijah R Behr...
https://pubmed.ncbi.nlm.nih.gov/33797288Actively Recruiting
All Genders
ID06898307
Utility of Gene Test Analysis for Diagnosis, Prognosis and Treatment of Patients With Genetic Arrhythmic Heart Disease: the ARRHYTHMIC GENE-HEART
Led by University Hospital of Ferrara · Updated on 2025-03-27
200
Participants Needed
1
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This observational study focuses on patients evaluated at the specialized Cardiogenetic Center within the Cardiology Department of the University of Ferrara, Italy. It aims to collect detailed clinical, genetic, and electrophysiological information from individuals with suspected or confirmed genetic arrhythmogenic heart conditions. The goal is to improve understanding of the genetic causes and clinical impact of inherited arrhythmias and systemic syndromes, supporting better diagnosis and personalized care. No experimental treatments are involved as this is a registry study. Data collected includes patient demographics, family history, clinical symptoms, diagnostic results, and treatment outcomes. The registry supports long-term follow-up to observe the natural progression of arrhythmogenic disorders and to evaluate the effectiveness of various therapies over time. Participants will be monitored through regular data collection on health outcomes such as death rates, heart failure, and arrhythmia events at one and five years. The study also tracks the need for devices like pacemakers or defibrillators and genetic mutation types. This long-term observational approach helps identify risk factors for adverse events and informs future research and clinical guidelines, with participation lasting several years until the study end date in 2035.
CONDITIONS
Brief Title
Utility of Gene Test Analysis for Diagnosis, Prognosis and Treatment of Patients With Genetic Arrhythmic Heart Disease: the ARRHYTHMIC GENE-HEART
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
- Patients evaluated at the Cardiogenetic Center of the University of Ferrara in Ferrara, Italy
- Having a proven cardiogenetic disease
You will not qualify if you...
- Refusal to provide informed consent
- Patients not having a cardiogenetic disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Diagnostic Evaluation
Duration - At the time of genetic analysis
Participants undergo genetic and clinical evaluations to assess their cardiogenetic disease and related arrhythmic conditions.
Long-term Monitoring
Duration - Up to 5 years
Participants are observed over several years to track clinical outcomes, including heart failure, arrhythmias, and survival.
Regular follow-up visits over 5 years
Trial Site Locations
Total: 1 location
1
Department of Cardiology, University Hospital of Ferrara
Ferrara, Italy, 44124
Actively Recruiting
Loading map...
Research Team
C
Cristina Balla, MD PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.
Katja Zeppenfeld, Jacob Tfelt-Hansen, Marta de Riva...
https://pubmed.ncbi.nlm.nih.gov/36017572Genetic testing for inherited cardiac disease.
Arthur A M Wilde, Elijah R Behr
https://pubmed.ncbi.nlm.nih.gov/23900354HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013.
Silvia G Priori, Arthur A Wilde, Minoru Horie...
https://pubmed.ncbi.nlm.nih.gov/24011539